Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotechnology company, ImmunoGen
So what: Trastuzumab emtansine, previously known as T-DM1, is an experimental drug targeting patients with metastatic HER2-positive breast cancer. In phase three results released very early this morning, the Roche and ImmunoGen drug was shown to significantly extend patients' lives when compared to GlaxoSmithKline's
Now what: ImmunoGen's Targeted Antibody Payload technology has the potential to be the cornerstone combination drug of the future, and the success of trastuzumab emtansine is a key part of that. Aside from Seattle Genetics
Craving more input? Start by adding ImmunoGen to you free and personalized Watchlist so you can keep up on the latest news with the company.